P7C3-A20

P7C3-A20 is an activator of nicotinamide phosphoribosyltransferase (Nampt), the rate-limiting enzyme in the NAD⁺ salvage pathway, and a derivative of P7C3 (Item No. 16682).¹ It activates Nampt in a coupled-enzyme assay at 0.3-3 µM and increases NAD⁺ levels in U2OS osteosarcoma cells depleted of NAD⁺ by doxorubicin (Item No. 15007). P7C3-A20 (10 mg/kg) restores brain NAD⁺ levels, reverses tau phosphorylation, reduces neuroinflammation, and reverses learning and memory deficits and anxiogenic behavior in aged animals in the amyloid-driven 5XFAD mouse model of Alzheimer’s disease.² It also normalizes the expression of 46 proteins in 5XFAD mouse brain that are also altered in patients with Alzheimer’s disease and reverses advanced disease in the tau-driven PS19 mouse model of Alzheimer’s disease. P7C3-A20 (10 mg/kg) decreases contusion volume, increases neurogenesis, and improves learning and memory in a rat model of traumatic brain injury (TBI).³

WARNING This product is not for human or veterinary use.

1. Wang, G., Han, T., Nijhawan, D., et al. P7C3 neuroprotective chemicals function by activating the rate-limiting enzyme in NAD salvage. Cell 158(6), 1324-1334 (2014).

2. Chaubey, K., Vázquez-Rosa, E., Tripathi, S.J., et al. Pharmacologic reversal of advanced Alzheimer’s disease in mice and identification of potential therapeutic nodes in human brain. Cell Rep. Med. 7(1), 102535 (2026).

3. Blaya, M.O., Bramlett, H.M., Naidoo, J., et al. Neuroprotective efficacy of a proneurogenic compound after traumatic brain injury. J. Neurotrauma 31(5), 476-486 (2014).